(Q42997607)

12 November 2017

A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C. (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

Martinot-Peignoux M

1

1 reference

12 November 2017

Boyer N

2

1 reference

12 November 2017

Le Breton V

3

1 reference

12 November 2017

Le Guludec G

4

1 reference

12 November 2017

Castelnau C

5

1 reference

12 November 2017

Akremi R

6

1 reference

12 November 2017

Marcellin P

7

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 March 2000

1 reference

12 November 2017

1 reference

12 November 2017

31

1 reference

12 November 2017

3

1 reference

12 November 2017

726-729

1 reference

Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications

12 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310324

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310324

7 January 2021

Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310324

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310324

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310324

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310324

7 January 2021

Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310324

7 January 2021

A comparison of reverse transcription-polymerase chain reaction and branched-chain DNA assays for hepatitis C virus RNA in patients receiving interferon treatment. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310324

7 January 2021

Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310324

7 January 2021

Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310324

7 January 2021

Implications of variations of "conserved" regions of hepatitis C virus genome

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310324

7 January 2021

Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by quantiplex HCV RNA assay versions 1 and 2, Roche Monitor assay, and an in-house limiting dilution method

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310324

7 January 2021

Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310324

7 January 2021

Quantification of serum hepatitis C virus RNA.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310324

7 January 2021

Identifiers

DOI

10.1002/HEP.510310324

1 reference

12 November 2017

1 reference